BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27984642)

  • 1. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Chang CK; Zhao YS; Xu F; Guo J; Zhang Z; He Q; Wu D; Wu LY; Su JY; Song LX; Xiao C; Li X
    Br J Haematol; 2017 Feb; 176(4):600-608. PubMed ID: 27984642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
    Zhao YS; Guo J; Xu F; Wu D; Wu LY; Song LL; Xiao C; Li X; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):124-128. PubMed ID: 28279036
    [No Abstract]   [Full Text] [Related]  

  • 3. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eprenetapopt (APR-246) and Azacitidine in
    Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
    J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
    Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
    Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
    Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
    Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
    Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
    Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW;
    Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
    Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
    Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.